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OBJECTIVES The purpose of this study was to evaluate mortality and readmission rates of heart failure
(HF) patients after major noncardiac surgery.
BACKGROUND There is a lack of generalizable outcome data on HF patients undergoing major noncardiac
surgery because previous studies have been limited to a few academic centers or have not
focused on this group of patients.
METHODS Using the 1997 to 1998 Standard Analytic File 5% Sample of Medicare beneficiaries, we
identified patients with HF who underwent major noncardiac surgery. A multivariable logistic
regression model was used to provide adjusted mortality and readmission rates in patients
after noncardiac surgery. Patients with coronary artery disease (CAD) and all other remaining
patients (Control) who had similar surgery served as reference groups.
RESULTS Of 23,340 HF patients and 28,710 CAD patients, 1,532 (6.56%) HF patients and 1,757
(6.12%) CAD patients underwent major noncardiac surgery. There were 44,512 patients in
the Control group with major noncardiac surgery. After accounting for demographic
characteristics, type of surgery, and comorbid conditions, the risk-adjusted operative mortality
(death before discharge or within 30 days of surgery) was HF 11.7%, CAD 6.6%, and Control
6.2% (HF vs. CAD, p  0.001; CAD vs. Control, p  0.518). The risk-adjusted 30-day
readmission rate was HF 20.0%, CAD 14.2%, and Control 11.0% (p  0.001).
CONCLUSIONS In patients 65 years of age and older, HF patients undergoing major noncardiac surgery suffer
substantial morbidity and mortality despite advances in perioperative care, whereas patients
with CAD without HF have similar mortality compared with a more general
population. (J Am Coll Cardiol 2004;44:1446–53) © 2004 by the American College of
Cardiology Foundationm
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nver the last 25 years, there has been steady improvement in
he care of patients undergoing major noncardiac surgery.
owever, changes in the epidemiology of patients undergoing
urgery may make future care more complicated. Progress in
he treatment of chronic diseases such as hypertension, diabe-
es, and coronary artery disease (CAD) and the ageing popu-
ation are increasing the prevalence of heart failure (HF) (1,2).
lready, there are an estimated 550,000 new cases of HF each
ear and an estimated prevalence of five million patients with
ver 75% age 65 years and older (3–5). In addition, the elderly
s an important group undergoing noncardiac surgery at in-
reasing rates (6). Therefore, examination of outcomes in these
nderstudied, yet higher risk groups will help clarify areas
eeded for improvement.
Coupled to the growing HF and elderly populations is
he dramatic increase in the number of surgical procedures.
ince 1990, the number of procedures has increased from 27
illion to nearly 40 million. There are over 10 million major
oncardiac surgeries performed each year, with the largest
roup in patients age 65 years and over (6).
From the *Division of Cardiology, Department of Medicine, Duke University
edical Center and †Duke Clinical Research Institute, Durham, North Carolina. Dr.
ernandez is partly supported by an American College of Cardiology Foundation/
erck grant.
Manuscript received February 2, 2004; revised manuscript received June 2, 2004,nccepted June 22, 2004.Previous studies emphasize ischemic heart disease as the
ost important risk for perioperative complications, but HF
as been equally important (7–10). Furthermore, little is
nown about how HF patients fare with perioperative recom-
endations. In fact, there is little to guide clinicians on how to
anage patients with HF through the perioperative period
11). The most widespread recommendation of using beta-
lockers in patients at risk for perioperative complications has
nly been studied in 30 patients in clinical studies (11–15).
hus, although numerous advances in perioperative care have
ocused on the management of coronary disease, it is unknown
ow this modifies perioperative risk among HF patients.
Finally, previous studies evaluating perioperative risk of
omplications during noncardiac surgery have several limi-
ations. In general, studies evaluating perioperative risk have
een limited to only one or a few academic centers, so it is
ifficult to know what the rate of perioperative complica-
ions is in the general population or routine practice. Most
tudies were also limited to inpatient mortality and failed to
xamine mortality in the early post-discharge period. In
ddition, readmission rates have not been routinely exam-
ned (7,9,10,16). Therefore, we sought to evaluate mortality
nd readmission rates of HF patients after major noncardiac
urgery using a database from Medicare that provides a
ational representation of elderly patients undergoing major
oncardiac surgery.
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ata source. The primary data source was the Medicare
laims files provided by the Center for Medicare and
edicaid Services from 1997 to 1998. The standard analytic
le is a nationally random sample of 5% of the Medicare
eneficiaries and includes all in-patient hospitalizations that
re billed to Medicare. The files contain demographic and
imited clinical information such as age, gender, race,
ischarge status including death, up to 10 discharge diag-
oses, and 6 procedures identified by International Classi-
cation of Diseases, 9th Revision (ICD-9) and Current
rocedural Terminology codes (17,18). Mortality data came
rom the Medicare records and date-of-death files. All
edicare beneficiaries in the fee-for-service system age 65
ears or older were eligible for the study.
atient populations. To avoid classifying patients who
uffered HF or CAD as complications of surgery who did
ot have such disease before the procedure, we first identi-
ed all patients with HF or CAD from a non-surgical
dmission who were discharged alive. Once identified, these
ohorts were followed for subsequent hospitalization for
oncardiac surgery.
Our study population consisted of three separate co-
orts consisting of patients with a history of HF, a
istory of CAD, and the remaining patients who had
ajor noncardiac surgery (Control). For the HF cohort,
e identified patients who were admitted with a primary
iagnosis of HF based on ICD-9 codes (402.01, 402.11,
02.91, 402.92, 425.0, 428.x) (19). Patients who survived
able 1. Baseline Demographics
(n
ean age (yrs  SD) 78
on-white (%)
ale (%)
ime (days) from index admission to surgery (mean  SD) 151
harlson index (mean  SD) 1.
SRD (%)
schemic heart disease (%)
dmitted to a teaching hospital (%)
dmitted from a SNF (%)
ischarged to a SNF (%)
urgery admission type
Elective
Urgent
Emergent
Abbreviations and Acronyms
CAD  coronary artery disease
HF  heart failure
ICD-9  International Classification of Diseases-
9th Revision
SNF  skilled nursing facilityAD  coronary artery disease; ESRD  end-stage renal disease; HF  heart failure; n/o discharge and subsequently had a major noncardiac
urgery in the following year were included into our HF
ohort. The HF cohort was further stratified into two
roups according to secondary diagnosis of CAD (ICD-9
odes 410.x, 411.x, 412, 413, 414). We identified two
dditional groups for comparisons: CAD—patients who
ad CAD but no HF in the previous year; and Control—
ll remaining patients who underwent major noncardiac
urgery without hospitalization for HF or CAD during
he previous year.
Major noncardiac surgeries were identified using appro-
riate Current Procedural Terminology-4th Revision codes
lassified into five groups (Vascular, Abdominal, Thoracic,
rthopedic, and Other) and as elective, urgent, or emergent
18). Only patients with a primary Diagnosis Related Group
elated to the primary procedure code of a major noncardiac
urgery were included into the cohorts. Minor procedures
uch as breast surgery, endoscopies, and superficial proce-
ures were excluded. To avoid counting patients more than
nce, only the first episode of noncardiac surgery was
ncluded in the study.
ata analysis. The primary outcome of the study was
perative mortality, defined as death before hospital dis-
harge or within 30 days after the procedure. Other out-
omes analyzed were mortality 30 days after discharge,
eadmission within 30 days of surgery for any reason, length
f stay, and days in the intensive care unit.
Patients were characterized according to demographic
haracteristics and comorbid illness as described by the
harlson index (19). We also considered other variables
uch as teaching status of the hospital, admissions to and
rom skilled nursing facilities (SNF), and readmissions
etween index identification and surgery. Categorical vari-
bles were compared between groups using the Pearson
hi-square test, and continuous variables were compared
sing the non-parametric Kruskal-Wallis test.
Logistic regression models were developed to examine
he relationship of major noncardiac surgery mortality and
532)
CAD
(n  1,757)
Control
(n  44,512) p Value
7.6 76.0  6.5 77.4  7.5 0.001
9.2 9.9 0.001
55.9 41.4 0.001
109.2 148.2 107.4 n/a 0.441
1.91 1.64 1.95 1.51  2.17 0.001
4.5 1.9 0.001
100 20.8 0.0001
18.3 15.5 0.001
1.2 1.3 0.001
17.9 26.9 0.001
0.001
50.0 48.6
21.7 21.3
28.1 30.7HF
 1,
.7
15.6
39.8
.4
67 
11.5
45.2
17.5
2.7
29.8
32.0
26.0
41.7a  not applicable; SNF  skilled nursing facility.
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Heart Failure and Noncardiac Surgery October 6, 2004:1446–53aving a history of HF or CAD. Variables were selected for
he final model by strength of association with p  0.05.
Kaplan-Meier curves were generated to evaluate mortality
0 days after admission based on urgency of the procedure.
he log-rank test was used to compare results.
ESULTS
n the year after the index HF hospitalization, 1,532 (6.6%)
f 23,340 identified HF patients had a major noncardiac
urgery in a mean time of 151 days after the index
ospitalization. Ischemic heart disease was indicated as a
econdary diagnosis in 45.2% of HF patients. During the
ear after the index CAD hospitalization, 1,757 (6.1%) of
8,710 identified CAD patients had a major noncardiac
urgery in a mean time after the index hospitalization of 148
ays. Of those in the HF cohort, 48.0% had no readmis-
ions between index admission and surgery, whereas 28.7%
ad one readmission and 13.3% had two readmissions.
ithin the CAD cohort, 59.8% had no readmissions before
urgery, whereas 22.5% had one readmission and 10.4% had
wo readmissions before surgery. The primary diagnosis to
ualify for the HF cohort was 428.0 (HF) in more than 90%
f the patients. The primary diagnosis to qualify for the
AD cohort was chronic ischemic heart disease (414.01) in
0% of the patients and myocardial infarction (410.x) in
8% of the patients. Patients classified with these two
iagnoses accounted for the majority of the subsequent
perative mortality with 42.4% of the operative deaths
oded as chronic ischemic disease (414.x) and 47.5% of the
eaths coded as myocardial infarction (410.x) on entry into
he CAD cohort. The other diagnostic codes for interme-
iate coronary syndrome (411.x), old infarction (412.x), and
ngina (413.x) accounted for the remaining operative mor-
ality. Over the study period, 44,512 patients remained who
ad a major noncardiac surgery but who did not have HF or
AD.
Patients with HF were older and more likely to be female
nd nonwhite compared with the CAD and control cohorts
Table 1). The time to surgery was similar in the HF and
AD cohorts. The HF cohort had a higher Charlson index
han the CAD and the control cohorts, indicating higher
revalence of comorbid conditions. There was also a higher
ate of end-stage renal disease in the HF cohort than the
ther groups. Admissions to a teaching hospital for surgery
ccurred more often for CAD patients than patients in the
Table 2. Frequency of Procedure Type by Coh
HF
(n  1,532) (
Abdominal (%) 22.7
Orthopedic (%) 26.1
Thoracic (%) 8.2
Vascular (%) 28.7
Other (%) 14.4
Abbreviations as in Table 1.F or control cohort. Very few patients were admitted for iurgery from a SNF, but a much larger number were
ischarged to a SNF. The HF patients were more likely to
e discharged to a SNF compared with the CAD and
ontrol patients. The HF patients also had a higher rate of
mergent or urgent surgeries than the CAD and control
atients.
The distribution of procedure types is shown in Table 2.
he control cohort had mostly orthopedic procedures,
hereas the HF and CAD cohorts underwent vascular
rocedures more often. Procedures classified as “other”
onsisted of extremity amputations, prostate surgeries, neu-
osurgeries, gynecologic surgeries, and nonvascular head and
eck procedures. Table 3 shows the outcomes by procedure
ype.
For the logistic regression model, significant variables
ncluded age, gender, Charlson index, procedure type,
dmission from a SNF, and urgency of surgery (Table 4).
ge was transformed into two variables, above and below 75
ears, to satisfy model assumptions. Race and teaching
tatus of the hospital were also evaluated but were not
ncluded in the final model owing to lack of statistical
ignificance.
utcomes. The primary outcome of operative mortality
death before discharge or within 30 days of the procedure)
as 11.7% after risk adjustment in the HF cohort compared
ith 6.6% in the CAD cohort and 6.2% in the control
ohort (HF vs. CAD, p  0.001; CAD vs. Control, p 
.518). Risk-adjusted inpatient mortality during surgery
dmission was 7.9% in the HF cohort, whereas the CAD
nd control cohorts had lower mortality of 4.6% and 4.1%,
espectively (HF vs. CAD, p  0.001; CAD vs. Control, p
0.328). Mortality 30 days after discharge also showed
imilar results, 6.5% in the HF cohort and 3.3% and 3.2%,
espectively for the CAD and the control group (HF vs.
AD, p  0.001; CAD vs. Control, p  0.904) (Table 5).
The HF cohort was stratified into two groups of patients
ith CAD criteria as a secondary diagnosis and without.
owever, there was no difference between these two strata
n the final model, so all adjusted outcomes are reported
rouped together within the HF cohort (p  0.304).
bserved 30-day mortality in HF patients without CAD
as similar or higher than HF patients with CAD. Heart
ailure patients with and without CAD had a two- to
our-fold higher mortality rate than the CAD and control
roups (Table 6). To ensure that our results were not unduly
D
1,757)
Control
(n  44,512) p Value
.1 23.5 0.702
.5 45.4 0.001
.9 6.6 0.001
.3 16.7 0.001
.3 7.8 0.001ort
CA
n 
23
22
9
36
8nfluenced by end-stage renal disease, these patients were
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utcomes including operative mortality and 30-day read-
ission rate.
During the surgery admission, the length of hospital stay
nd intensive care unit stay was longer in HF patients. All
hree groups were readmitted within an average of approx-
mately 13 days. The HF patients were admitted 20.0% of
he time compared with 14.2% of the CAD patients and
1.0% of the control patients (HF vs. CAD, p  0.001;
AD vs. Control, p  0.001). The most common primary
iagnosis for readmission in all groups related to the initial
urgery. However, the second most common primary diag-
osis in the HF cohort was HF (428.0).
Kaplan-Meier curves also demonstrate the higher mor-
ality rate of HF patients after surgery regardless of proce-
ure urgency (Fig. 1). The CAD and the control cohorts
ad a similar mortality throughout the study period.
Background rates of mortality for HF patients without
urgery who were admitted for HF were 5.4% at 30 days
fter discharge from the index admission, 22.4% at six
onths and 33.4% at one year. The CAD patients who did
ot have surgery but were discharged alive from the index
dmission had a 30-day mortality of 2.2%, 6-month mor-
ality of 7.3%, and 1-year mortality of 10.7%.
ISCUSSION
n this study, the largest description of HF patients under-
oing major noncardiac surgery, HF patients had a twofold
igher mortality and readmission rate than those with
oronary disease or the control population. The markedly
igher mortality was apparent across all types of surgeries
ith a two- to four-fold increase in mortality for HF
atients compared with all others. This is especially impor-
ant when considering that more than 75% of all HF
atients are older than 65 and have the highest incidence of
ajor noncardiac surgeries (6,20). Heart failure patients
ave higher mortality rates over time compared with other
able 4. Odds Ratio for 30-Day Mortality
Effect
Odds
Ratio
95% Wald
Confidence Limits
F vs. control 2.187 1.880 2.545
AD vs. control 1.078 0.884 1.315
F vs. CAD 2.029 1.592 2.585
-yr increase in age (75 yrs) 1.025 1.007 1.043
-yr increase in age (75 yrs) 1.072 1.065 1.080
ale vs. female 1.290 1.190 1.398
-U increase in Charlson index 1.117 1.101 1.134
horacic vs. orthopedic 3.498 3.028 4.041
bdominal vs. orthopedic 2.525 2.278 2.799
ther vs. orthopedic 2.066 1.775 2.405
ascular vs. orthopedic 2.201 1.937 2.500
mergent vs. elective 4.002 3.612 4.435
rgent vs. elective 2.635 2.355 2.948
dmitted from SNF 1.895 1.509 2.378
bbreviations as in Table 1.patients, but the background mortality rate of HF patientsT P M 3 R M I D C
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Heart Failure and Noncardiac Surgery October 6, 2004:1446–53fter a non-surgical hospitalization was only 5.4%. Interest-
ngly, the diagnosis of coronary disease was less important in
F patients because those with and without coronary
isease had similarly poor outcomes. Although the differ-
nce in the mortality rates between the CAD and the HF
ohorts may be due to other unmeasured clinical factors
uch as revascularization or beta-blocker use, it is clear that
F patients known to be high risk need great attention.
Previous studies have demonstrated that HF is an impor-
ant risk factor, but the magnitude may be underappreci-
ted. Heart failure has been either the most significant risk
actor for perioperative complication or among the highest
n previous studies (7,9,10,16,21,22). Although previous
trategies for preoperative risk stratification emphasized the
dentification of coronary disease, the importance of HF is
lear from this study (8,11). In comparison to testing and
nterventions for coronary disease, which often delay surgery
or weeks, early identification and optimization of HF may
e done easily in the future with advances in diagnostics and
herapies.
The similarity in mortality between CAD patients without
F and the general population supports the notion that these
atients do not routinely need additional testing unless re-
uired for unstable symptoms or if beta-blocker therapy peri-
peratively is contraindicated (23). However, our study dem-
nstrates that the presence of HF substantially increases the
able 5. Outcomes
HF
(n  1,532)
rimary outcome: 30-day mortality (95% CI)
Observed (%) 15.4 (13.6–17
Risk-adjusted (%) 11.7 (10.2–13
ortality during surgery admission (95% CI)
Observed (%) 10.7 (9.2–12.0
Risk-adjusted (%) 7.9 (6.8–9.0)
0-day mortality in discharged patients (95% CI)
Observed (%) 8.4 (6.9–9.9)
Risk-adjusted (%) 6.5 (5.4–7.6)
eadmission rate within 30 days (95% CI)
Observed (%) 23.6 (21.5–25
Risk-adjusted (%) 20.0 (18.3–21
ean length of stay (days  SD) 11.0  10.6
ean length of ICU stay (days  SD) 4.9  6.0
atients with an ICU stay (%) 44.7
ean time to readmission (days  SD) 13.0 8.5
p value for difference between HF and CAD groups; p value for difference between
0.001).
Abbreviations as in Tables 1 and 3.
Table 6. Observed 30-Day Mortality by Coho
by Presence of CAD
Abdominal
(%)
Orthop
(%
HF with CAD 28.4 20.
HF without CAD 35.9 18.
CAD 12.8 5.
Control 12.9 4.Abbreviations as in Table 5.isk of mortality, which is not a component of suggested
lgorithms. Therefore, evidence-based strategies are needed for
onstructing recommendations in professional guidelines to
anage HF patients perioperatively.
In comparison to some studies, the overall mortality rate
as higher, but compared with other Medicare studies it is
imilar. In general, earlier studies have been in one or a few
cademic centers or restricted to the Veterans Administra-
ion system (7,9,10,16,24,25). Most studies taking place at
ne or a few academic centers only report in-patient
ortality, which is lower than in our study (10,16). These
tudies differ from ours largely with respect to the age of the
tudy population, but also because of other patient comor-
idities, with previous studies having younger, healthier
atients compared with our study. Studies of the Medicare
opulation had similar mortality rates as this study, with
0-day mortality of 7% in a study by Fleisher et al. (26) in
ascular surgery and 4% to 20% depending on the procedure
n a study by Birkmeyer et al. (27). By using a national
ample, our study provides an assessment of outcomes when
atients are not necessarily part of a study emphasizing the
eduction of perioperative morbidity. Furthermore, this
tudy helps provide important insight into the outcomes of
lderly patients who undergo noncardiac surgery in a variety
f hospital settings where it is known that there is variation
n the quality of care (28,29).
CAD
(n  1,757)
Control
(n  44,512) p Value*
6.6 (5.5–7.8) 6.1 (5.9–6.3)
6.6 (5.4–7.8) 6.2 (6.0–6.4) 0.001
5.0 (4.0–6.1) 4.1 (3.9–4.2)
4.6 (3.6–5.5) 4.1 (3.9–4.3) 0.001
2.9 (2.1–3.7) 3.3 (3.1–3.5)
3.3 (2.4–4.3) 3.2 (3.0–3.4) 0.001
15.5 (13.8–17.2) 10.9 (10.6–11.2)
14.2 (12.5–15.8) 11.0 (10.7–11.3) 0.001
9.3 10.5 8.9 11.1
4.2 5.2 4.1 5.6 0.015
48.2 28.0 0.053
13.3 8.5 13.2 8.4 0.709
and control group is 0.05 except for readmission rate (0.001) and % ICU stay
ocedure Type, and Heart Failure Stratified
Thoracic
(%)
Vascular
(%)
Other
(%)
28.1 14.7 20.3
35.5 12.6 30.2
17.6 4.6 12.4
16.6 6.5 8.5.3)
.1)
)
.8)
.8)
CADrt, Pr
edic
)
8
3
8
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(CAD)/Control, p  0.001. CAD versus Control, p  NS. Solid lines 
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old higher for HF patients than patients with coronary
isease and the control population. Despite having a slightly
onger length of stay, there was a 20% readmission rate for
ny cause. There appears to be an important need for
urveillance of patients with a history of HF in the hospital
o ensure that discharge is appropriate, plus close follow-up
f outpatients to prevent readmissions. A multidisciplinary
pproach may prevent readmissions, ensure appropriate
edication use, and hopefully prevent excess mortality as
one currently in some centers for patients admitted with
F exacerbations (30,31).
There are many possible reasons why HF patients fare
orse during the perioperative period, with type and ur-
ency of surgery being the most important. Although our
tudy attempted to adjust for mix and risk of surgery type,
here may be unmeasured factors related to the type of
urgery performed in HF patients that cannot be fully
ccounted for in this study. Patients with severe HF may
ndergo procedures to treat complications of HF as their
everity of illness increases. In our study, HF patients
nderwent urgent and emergent surgeries more often than
ther patients that entailed additional risk compared with
lective procedures. Accordingly, our study highlights a
eed for research in HF patients, especially those undergo-
ng urgent and emergent surgery, to identify those patients
t the highest risk and to attempt a therapeutic intervention
o reduce the risk. This is possible because, in general, there
re few procedures that cannot be delayed for some period
n an attempt to stabilize other conditions such as HF. Also,
lective surgeries in HF patients may be unduly delayed
ntil absolutely necessary, causing more emergent or urgent
rocedures to be performed, providing another opportunity
or the risk stratification of HF patients who have surgical
eeds.
Other non-surgical issues may increase the risk of HF
atients. There may be a lower use of beta-blockers perio-
eratively in patients with moderate to severe HF because of
emodynamic concerns that cannot be determined from our
ata. During the study period, the penetrance of beta-
lockers may be lower in HF patients compared with those
ith coronary disease, but this continues to be a problem
espite routine recommendations (32). There may also be a
ower use of revascularization procedures in HF patients.
owever, these factors are unlikely to account for the
ajority of the mortality difference found in this study.
linically, it may be difficult for physicians to assess wors-
ning HF symptoms because patients are limited in other
ays for which surgery is required. The lack of good
hysical examination skills and fluid shifts during surgery
nd the inability to respond to stress may also impact HF
atients’ surgical outcomes.
Our study raises the question of what transpires periop-
ratively in HF patients beyond ischemia from underlying
oronary disease. Other factors may play a role, because ourigure 1. Kaplan-Meier curves of (A) survival after elective surgery, (B)
urvival after urgent surgery, and (C) survival after emergent surgery. Log-rank
est used for comparisons. Heart failure (HF) versus coronary artery diseasetudy shows that HF patients without a history of coronary
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Heart Failure and Noncardiac Surgery October 6, 2004:1446–53isease had similar mortality as those with coronary disease.
urthermore, there have not been any significant studies in
ver a decade specifically characterizing the reasons HF
atients do poorly (33,34). Advances over the last decade in
he understanding of HF should be applied to new inves-
igations of the pathophysiology of perioperative complica-
ions in HF patients beyond the classic supply/demand
schemia hypothesis used for patients with coronary disease
35,36).
Although we cannot characterize the HF population into
hose with systolic dysfunction and those without, future
tudies should investigate the differences of these two types
f HF undergoing major noncardiac surgery. Previous
tudies did not evaluate HF with preserved systolic function
n the perioperative setting because its importance and
haracteristics did not become apparent until the last several
ears (37,38). The elderly have a high prevalence of HF
ith preserved systolic function that may be important in
he perioperative setting because of poor tolerance to vol-
me overload, a common perioperative event. The baseline
emographics show a majority of women in the HF cohort,
hich is consistent with other studies of HF in the elderly.
hus, there are likely many patients with HF and preserved
ystolic function who are at risk for postoperative compli-
ations.
Finally, future studies are also needed to address how to
educe the perioperative risk of cardiac complications in HF
atients, including more extensive studies of beta-blockers,
tatins, and angiotensin-aldosterone antagonism (39). Al-
hough the long-term benefit of beta-blockers is established
n HF patients, several issues may arise over the short term
hen attempting to titrate beta-blockers over a few days as
pposed to several weeks as normally done in outpatient HF
anagement (40). Heart failure patients who present for
rgent or emergent procedures are high risk, and procedures
o quickly identify their level of compensation and optimize
heir HF before undergoing a major surgery need to be
dentified. Future work should also clarify the role of right
atheterization of advanced HF patients in the perioperative
etting as there is little evidence for this procedure despite
ome recommendations (41,42).
tudy limitations. While Medicare is the one of the few
ources to examine national outcomes in men and women
ndergoing noncardiac surgery, it is limited in the extent
nd accuracy of clinical information (43). Previous work has
ointed to the limitations of using ICD-9 codes for the
evelopment of models for assessing surgical quality, and we
annot assume that all factors accounting for the outcomes
ave been included in our models (44). This includes the
ack of data for medication use such as beta-blockers or
ther medications used to treat cardiovascular disease. To be
dentified as HF or CAD, patients had to have a previous
ospital admission for entry into those cohorts, respectively.
his may increase their risk of postoperative complications,
nd patients with HF or CAD who did not have a hospital
dmission during the identification period were not specif-cally studied. Our study only included patients age 65 years
nd older, but complications in this group are important,
ith at least four million major noncardiac surgeries each
ear as well as the predicted growth in this population
6,45–47). We cannot determine accurately if readmissions
ere a result of surgical complications or if readmissions
ere due to non-surgical issues such as HF. Even if there
ere readmissions for surgical issues, HF patients may have
roblems related to their disease such as edema, poor
ealing, malnutrition, electrolyte abnormalities, renal insuf-
ciency, and anemia.
ONCLUSIONS
n patients age 65 years and older, HF patients suffered
ignificant morbidity and mortality after undergoing non-
ardiac surgery. Patients with coronary disease undergoing
ajor noncardiac surgery had better outcomes than HF
atients and similar outcomes to the control cohort. Future
esearch is needed to understand why HF patients do poorly
ith noncardiac surgery to prevent perioperative complica-
ions.
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